SpaceOAR® Hydrogel as part of our standard pre-radiotherapy treatment.

We believe patients deserve the best and that’s why we offer SpaceOAR® Hydrogel as part of our standard pre-radiotherapy treatment.

We design our care to help give patients the best possible life outcomes. Which is why since January 2018 we’ve successfully delivered 200 SpaceOAR® Hydrogel insertions as part of our standard pre radiotherapy treatment for men with prostate cancer, at no extra cost.

We offer a choice of 14 insertions sites in the UK with a further 10 in progress and 21 consultants available to deliver treatment.

What are the benefits of SpaceOAR® Hydrogel?

In a randomised clinical trial, at a median three-year follow-up, SpaceOAR® Hydrogel patients experienced reduced side-effects from prostate cancer radiation, including:

  • 67% maintained sexual potency 3***
    • A reduction in erectile disfunction (for men potent at baseline) 3
  • 73% relative reduction in rectal v701*
    • A reduction in bowel dysfunction1
  • 66% fewer clinically significant declines in urinary QOL 2**
    • A reduction in urinary incontinence2
  • 0% Late Grade 2 or higher rectal toxicity 2
    • A reduction in rectal toxicity from radiation exposure1
  • An overall improvement in quality of life, compared to patients who did not receive the implant.1

Contact us
For more information or to find out how to refer a patient contact us at your local GenesisCare centre.

References
1 Mariados, N. et al. 2015. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology biology physics. 92(5), pp. 971 – 977.
2 Hamstra, D. et al. 2017. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial Hamstra, Daniel A et al International Journal of Radiation Oncology. Practical Radiation Oncology. 97(5), pp. 976 – 985.
3 Hamstra, D. et al. 2018. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Practical Radiation Oncology. 8(1), pp. 7 – 15.
* average reduction when comparing pre and post-spacer treatment plans.
** defined as 2x the minimally important difference compared to control patients.
*** compared to 38% in the control group; of men who had erections sufficient for intercourse at baseline; median 3 years

Related articles

GenesisCare Centre for Radiotherapy at Cromwell Hospital

SABR for spinal lesions

World’s smartest radiotherapy treatment made available to NHS pancreatic cancer patients, without cost

Cancer treatment during Covid-19